Browsing by Subject "PD-L1"
Now showing items 1-4 of 4
-
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
(J Immunother Cancer, 2018-01-25)Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are ... -
First-line treatment of metastatic melanoma: role of nivolumab.
(Immunotargets Ther, 2017)Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape with increased survival ... -
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
(Rheumatology (Oxford, England), 2019-12)Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis. Because ... -
PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis.
(Bladder cancer (Amsterdam, Netherlands), 2019-11-22)<h4>Background</h4>Immune checkpoint inhibitors (ICI) are extremely expensive and most patients with metastatic urothelial carcinoma (mUC) do not benefit significantly from their use.<h4>Objective</h4>We performed a systematic ...
